THERE ARE MANY STAKHOLDERS WHO HAVE A ROLE TO PLAY IN BETTER HEALTH OUTCOMES
AND BETTER DATA WILL ENSURE THEY CAN FULFILL THEIR OBJECTIVES. THE HEALTHTAB + RASTR NETWORK SUPPORTS THEM AND MAKES IT POSSIBLE.

MEET CAROL
THE CONSUMER

Lives an active life, filled with a busy career, friends and travel.

She has three apps on her mobile device related to health.

Has purchased genetic testing online and regularly reads articles, follows thought leaders on social media for up to date trends in health, fitness and medical trends.

Experiences early stage rheumatoid arthritis and takes medications.

She’s looking to ensure her drug therapies are tailored to her and will not impact her liver in the long term, as she has read of drug-recalls and studies that concern her.

MEET PHIL
THE PHARMACIST

Experienced, knowledgeable and trusted by his customers.

Has seen big shifts in his business, particularly the impact of $3 Billion being removed from the industry in April 2018 by changes by the Government of Canada.

Looking to provide modern healthcare services that utilizes his expertise, client relationships and convenient locations.

Sees an expanded role for his profession to play as part of a total healthcare team.

MEET DIANE
THE DRUG MAKER

Recognizes the importance of consistent, reliable data for product development and improvement.

Sees the risk of recalls and litigation facing the industry from unforeseen complications once a therapy is in the at-large population.

Looking to build brand loyalty and a deeper relationship with her consumers.

Wants to demonstrate to the public, and regulators, that her company is committed to innovation and lowering costs.

YOUR RESEARCH CAPABILITIES JUST GOT BETTER

CLINICAL RESEARCH ORGANIZATIONS

Access to real world evidence (RWE) is vital, yet challenging to reliably produce.  The RASTR Network is the first point-of-care based system which provides direct consumer consent on targeted patient demographics, as well as harmonized, real-time reporting on customized data.


PHYSICIANS / CLINICIANS

Real-time monitoring makes remote care delivery and follow-ups easier.  Our solution can integrate seamlessly into patient heath records, allowing for results of testing to be remotely monitored in real-time. The HealthTab screen test means you can track patient progress, adherence and make evidence-based decisions on treatment recommendations.

NGO/NOT FOR PROFIT

Build a customized program to monitor known populations, and discover unknown populations, facing health concerns you focus on. Develop valuable data-points to drive attention of the donor base and policy-makers.

LIFE SCIENCE + BIOTECHNOLOGY 

Demonstrate the value of your products, monitor adherence and adverse events, such as liver toxicity, all while deepening the relationship with the consumer. Engaging consumers in self-care behaviours, quickly identify adverse reactions and engage them at critical milestones so as to improve their experience.

PRIVATE AND PUBLIC INSURERS

Leverage emerging technology to monitor consumer base to better understand their needs, resources required and service outcomes. Measure provider performance and patient benefit to reward effective care and efficiency, as well as incentivize program adherence. Utilize real world evidence to forecast and maximize value.

RESEARCH AND DEVELOPMENT

Realize new program offering opportunities on our network, customized for your clientele, and seamlessly API integrated across data-management software.  Capture the true experience of treated populations and target demographics and build a deeper understanding of health impacts over time. This includes New Disease Models, product development, general studies and more which are free of the inherent limitations of closed clinical trials and studies.

REGULATORY COMPLIANCE & PHARMACOVIGILANCE 

With great attention being paid by the public adverse events (AEs), regulators are creating programs which require better data and more consumer involvement, particularly with respect to liver toxicity.  It is critical to measure safety, efficacy and identify benefits across a treated population, as opposed to traditional clinical trial alone.

Turnkey System

2 panels, 21 results

  • Proven point-of-care screening system, designed to support pharmacists evolving role.
  • Empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease.
  • Simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.
  • Results can be printed in-store or accessed securely online.

The patient driven Rapid Access, Safety Test Reporting System (RASTR)

  • A network of HealthTab systems utilizing the Piccolo Analyzer in community pharmacies.
  • Running panels on consumers utilizing finger stick sample, monitoring up to 21 key bio-markers, and/or customizable tests.
  • Allows for API integration for better data flow and customization.
  • Provides harmonized, real-time data on consumer health.

RASTR MODEL

1. The client purchases the drug or other health product.

2. The pharmacy leases the analyzers at a reasonable cost to become a part of the network.

3. The drug maker pays to access the network and sponsors test fees for consumer.

  • Consumer provided the confidence in knowing how their health is performing.

  • Pharmacist and Physician deepen the relationship with the consumer and get actionable information to better support them.

  • Drug maker and other product manufacturers are able to measure product performance with realtime data and have the best possible consumer insights.

Pharmacists once were the front line of community healthcare and played a direct role as part of the health team. Over time, trends developed that reduced their extensive medical training to being simply retailers, limiting innovation and leading to inflation in costs and poor health outcomes. Today, government seeks out cuts to reign in out-of-control budgets and pharma has been an easy target. 

Avricore has a solution – innovate not only in products, but service. Adding accessible genomics and targeted health information at the community pharmacy.

1

Drive Prescriptions

2

Increase Customer Loyalty

3

Increase Medication Review Billing and Other Clinical Services Revenue

4

Improve Inter-Professional Collaboration with Physicians

5

Improve Pharmacy Customer Service Index

6

Improve Overall Patient Health Through Screening, Chronic Disease Management, and Medication Optimization

7

Improve Medication Adherence and Frequency of Script Refills

8

Increase Traffic to Pharmacy

9

Increase Overall Pharmacy Blended Margin

THE CURRENT ENVIRONMENT

67% OF CONSUMERS SUPPORT
ACCESSING HEALTHCARE DIGITALLY

The Global Consumer Insights Survey demonstrates consumers are accessing healthcare directly in ever increasing levels and ways.

Direct digital access means consumers have more control, better insights on their health choices.

Healthcare teams and product makers get better data, accessed easily, improving quality of care at reduced costs.

POINT-OF-CARE TESTING (POCT) MARKET PROJECTED TO HIT $36 BILLION (US) BY 2025

360 Research found the market is growing due to aging demographics, increases in certain illnesses and technological advancements.

Companies like Roche, Abbott, Johnson & Johnson, Siemens and more are developing a range of devices and systems.

They are doing this both independently and through M&A, as well as JV’s.

97% of patients have actionable genes for medication modification 1

1 of every 3 ADRs are caused by drugs with pharmacogenetics 2

190 FDA-approved drugs with pharmacogeneic information in their

labeling 3

1. Dawes, M. et al. Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ Open 4, E528–E534 (2016).

2.Chan, S. L. et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br. J. Clin. Pharmacol. 82, 1636–1646

3.FDA. Table

LIVER TOXICITY IS NOW A MAJOR CONCERN FOR REGULATORS

More than 900 drugs have been implicated in causing liver injury and it is the most common reason for a drug to be withdrawn from the market Chemicals often cause subclinical injury to liver which manifests only as abnormal liver enzyme tests.

Drug induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures.

More than 75% of cases of idiosyncratic drug reactions result in liver transplantation or death.

The US Government created the Drug-Induced Liver Injury Network (DILIN) established to collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements.

Ostapowicz et al. Drug-Induced Hepatotoxicity: A Review. Journal of Applied Pharmaceutical Science 02 (05); 2012: 233-243

CLINICAL TRIALS ARE NOT AS EFFECTIVE AS REAL WORLD EVALUATIONS (RWE)

Trial population (small) vs. treated population (big)

Trial length (weeks/months) vs chronic use (years)

Very young/old often not enrolled

Patients at complex disease stages often not enrolled

Co-morbidities

Other serious medical conditions

Use of associated medications

LACK OF ACCESS TO DATA IS THE BIGGEST CHALLENGE TO IMPLEMENTING RWE PROGRAMS
Source: Deloitte 2017 RWE Benchmark Survey

Health

Naturopaths, nutraceutical makers, dietitians

Insurance

Government, health and benefit providers

Food

Diet companies, grocers, sports nutrition

Data

Researchers, health authorities, government